Telitacicept for Myasthenia Gravis

Recruiting at 65 trial locations

Overseen By RemeGen

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: RemeGen Co., Ltd.

Disqualifiers: Autoimmune disease, Infection, Thymoma, Immunodeficiency, Malignancy, Cardiovascular, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 24 weeks

180 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to test the effectiveness and safety of telitacicept, a new treatment for generalized myasthenia gravis (gMG), a condition that causes muscle weakness. Participants will receive either telitacicept or a placebo (a substance with no active treatment) to compare the effectiveness of telitacicept against no treatment. This trial suits individuals diagnosed with gMG, who experience muscle weakness, and have specific antibodies in their blood. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to the development of a promising new treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that telitacicept is likely to be safe for humans?

Research has shown that telitacicept is generally safe for people with generalized myasthenia gravis. In a 48-week study in China, most patients tolerated telitacicept well, experiencing no serious side effects. Another study found that telitacicept can be effectively added to other treatments, indicating it works well alongside them.

These findings suggest that telitacicept is generally safe for treating myasthenia gravis, as several studies have tested it with positive safety results. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for myasthenia gravis?

Telitacicept is unique because it targets the BAFF and APRIL pathways, which are involved in the survival and activity of B cells. Unlike standard treatments for myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, or immunosuppressants, which manage symptoms or broadly suppress the immune system, telitacicept specifically reduces the B cells contributing to the disease. This precision could mean fewer side effects and more effective disease control, making researchers excited about its potential to change the treatment landscape for myasthenia gravis.

What evidence suggests that telitacicept might be an effective treatment for myasthenia gravis?

Research has shown that telitacicept, which participants in this trial may receive, may help treat generalized myasthenia gravis. In a study from China, patients taking telitacicept improved by 4.83 points more than those taking a placebo, a fake treatment used for comparison. Another study found that 98.1% of patients reported symptom improvement. This treatment is also well-tolerated, meaning it doesn't cause many side effects, even for people with hard-to-treat myasthenia gravis. These findings suggest telitacicept could effectively manage this condition. ^{1 2 3 5 6}

Are You a Good Fit for This Trial?

This trial is for adults over 18 with generalized myasthenia gravis, a muscle weakness condition. Participants must have certain antibodies and scores indicating moderate to severe symptoms but not solely ocular-related. They should have a confirmed diagnosis fitting specific MGFA clinical classifications.

Inclusion Criteria

My tests show positive for antibodies against AChR or MuSK.

MG-ADL score ≥6 points at screening and baseline with ocular-related score <50% of the total score

QMG score ≥11 points at screening and baseline

Exclusion Criteria

I am currently dealing with an infection.

I had thymoma within the last 5 years or a thymectomy within the last 6 months.

Patients having current or history of primary immunodeficiency

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive telitacicept or placebo in a double-blind manner to evaluate efficacy and safety in treating generalized myasthenia gravis

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension

Participants may opt into continuation of treatment with telitacicept long-term

What Are the Treatments Tested in This Trial?

Interventions

• Telitacicept

Trial Overview The study is testing Telitacicept's effectiveness and safety in treating generalized myasthenia gravis compared to a placebo. Patients will be randomly assigned to receive either the actual medication or an inactive substance.

How Is the Trial Designed?

Group I: Telitacicept Experimental Treatment 1 Intervention

Telitacicept

Group II: Placebo Placebo Group 1 Intervention

Placebo

Telitacicept is already approved in China for the following indications:

Approved in China as Tai'ai for:

• Systemic lupus erythematosus (SLE)

Who Is Running the Clinical Trial?

RemeGen Co., Ltd.

Lead Sponsor

Trials

84

Recruited

11,100+

Dr. Jianmin Fang

RemeGen Co., Ltd.

Chief Executive Officer since 2008

PhD in Molecular Biology

Dr. Ruyi He

RemeGen Co., Ltd.

Chief Medical Officer since 2023

MD

Published Research Related to This Trial

The virtual Myasthenia Gravis Impairment Index (vMGII) effectively correlates with other patient-reported outcomes, demonstrating its utility in assessing disease status during telephone consultations for 214 myasthenia gravis patients.

A vMGII score of 11.5 or higher reliably predicts a positive response on the Patient-Acceptable Symptom State (vPASS), with a sensitivity of 78.7% and specificity of 81.4%, indicating its effectiveness in monitoring disease progression even without in-person evaluations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index. Menon, D., Alnajjar, S., Barnett, C., et al.[2023]

The FDA has recently approved new therapies, including complement and Fc receptor inhibitors, for treating generalized myasthenia gravis, highlighting advancements in treatment options for this condition.

There is ongoing uncertainty regarding which patients will benefit most from these expensive therapies, prompting discussions on the need for better clinical trial readiness and biomarker development to guide future research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The best and worst of times in therapy development for myasthenia gravis. Benatar, M., Cutter, G., Kaminski, HJ.[2023]

A new sum score has been developed to define treatment-refractory generalized myasthenia gravis (TRgMG), which includes criteria such as disease severity and inefficacy of previous therapies, making it easier for clinicians to make treatment decisions.

This scoring system, created through a consensus of 12 experts and based on a thorough literature review, aims to clarify when eculizumab should be used and can also serve as a basis for inclusion criteria in future clinical studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus. Schroeter, M., Berger, B., Blaes, F., et al.[2022]

This systematic review aims to evaluate the effectiveness and safety of acupuncture as an adjuvant therapy for myasthenia gravis (MG) by analyzing randomized controlled trials (RCTs) from multiple databases, ensuring a comprehensive assessment.

The review will provide high-quality evidence regarding acupuncture's role in treating MG, with a focus on minimizing bias and ensuring rigorous trial quality assessment through established methods.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Acupuncture for patients with myasthenia gravis: A systematic review protocol. Shi, S., Ji, X., Wang, Y., et al.[2022]

Observational comparative effectiveness research (CER) offers a promising alternative to randomized controlled trials (RCTs) for evaluating treatments in myasthenia gravis (MG), addressing challenges like disease rarity and variability by using real-life clinical data from routine care.

Recent advancements, including the creation of common data elements for MG and a standardized web-based database, enhance the feasibility of conducting multisite CER studies, allowing for better comparisons of therapies and improved understanding of treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. Guptill, JT., Raja, S., Sanders, DB., et al.[2019]

Citations

1. ir.vorbio.com ir.vorbio.com/news-releases/news-release-details/telitacicept-demonstrates-sustained-efficacy-and-favorable

News Release In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a placebo adjusted 4.83-point improvement in MG ...

2. prnewswire.com prnewswire.com/news-releases/results-of-china-phase-iii-clinical-study-of-telitacicept-for-generalized-myasthenia-gravis-selected-for-oral-presentation-at-2025-aanem-annual-meeting-302559374.html

Results of China Phase III Clinical Study of Telitacicept for ... ... data from the Phase III study of telitacicept for myasthenia gravis. The results showed that 98.1% of patients achieved an improvement of ...

3. clinicaltrials.gov clinicaltrials.gov/study/NCT05737160

Study of Telitacicept in Generalized Myasthenia Gravis The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.

4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11095194/

Effectiveness and safety of telitacicept for refractory ... Telitacicept is a feasible and well-tolerated add-on therapy for refractory GMG, offering valuable clinical evidence for this novel treatment option.

5. emjreviews.com emjreviews.com/neurology/news/telitacicept-phase-iii-trial-results-for-generalized-myasthenia-gravis-aan-2025/

Telitacicept Phase III Trial Results for Generalized ... - EMJ New Phase 3 data presented at AAN 2025 demonstrate significant symptom improvements in patients with generalized myasthenia gravis treated ...

6. frontiersin.org frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1604786/full

protocol of a randomized controlled trial Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. Ther Adv Neurol Disord. (2024) ...